Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Standard
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. / Kröger, Nicolaus; Holler, Ernst; Kobbe, Guido; Bornhäuser, Martin; Schwerdtfeger, Rainer; Baurmann, Herrad; Nagler, Arnon; Bethge, Wolfgang; Stelljes, Matthias; Uharek, Lutz; Wandt, Hannes; Burchert, Andreas; Corradini, Paolo; Schubert, Jörg; Kaufmann, Martin; Dreger, Peter; Wulf, Gerald G; Einsele, Hermann; Zabelina, Tatjana; Kvasnicka, Hans Michael; Thiele, Jürgen; Brand, Ronald; Zander, Axel R.; Niederwieser, Dietger; Witte, de; Theo, M.
In: BLOOD, Vol. 114, No. 26, 26, 2009, p. 5264-5270.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
AU - Kröger, Nicolaus
AU - Holler, Ernst
AU - Kobbe, Guido
AU - Bornhäuser, Martin
AU - Schwerdtfeger, Rainer
AU - Baurmann, Herrad
AU - Nagler, Arnon
AU - Bethge, Wolfgang
AU - Stelljes, Matthias
AU - Uharek, Lutz
AU - Wandt, Hannes
AU - Burchert, Andreas
AU - Corradini, Paolo
AU - Schubert, Jörg
AU - Kaufmann, Martin
AU - Dreger, Peter
AU - Wulf, Gerald G
AU - Einsele, Hermann
AU - Zabelina, Tatjana
AU - Kvasnicka, Hans Michael
AU - Thiele, Jürgen
AU - Brand, Ronald
AU - Zander, Axel R.
AU - Niederwieser, Dietger
AU - Witte, de
AU - Theo, M
PY - 2009
Y1 - 2009
N2 - From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70). All but 2 patients (2%) showed leukocyte and platelet engraftment after a median of 18 and 22 days, respectively. Acute graft-versus-host disease grade 2 to 4 occurred in 27% and chronic graft-versus-host disease in 43% of the patients. Cumulative incidence of nonrelapse mortality at 1 year was 16% (95% confidence interval, 9%-23%) and significantly lower for patients with a completely matched donor (12% vs 38%; P = .003). The cumulative incidence of relapse at 3 years was 22% (95% confidence interval, 13%-31%) and was influenced by Lille risk profile (low, 14%; intermediate, 22%; and high, 34%; P = .02). The estimated 5-year event-free and overall survival was 51% and 67%, respectively. In a multivariate analysis, age older than 55 years (hazard ratio = 2.70; P = .02) and human leukocyte antigen-mismatched donor (hazard ratio = 3.04; P = .006) remained significant factors for survival. The study was registered at www.clinicaltrials.gov as #NCT 00599547.
AB - From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70). All but 2 patients (2%) showed leukocyte and platelet engraftment after a median of 18 and 22 days, respectively. Acute graft-versus-host disease grade 2 to 4 occurred in 27% and chronic graft-versus-host disease in 43% of the patients. Cumulative incidence of nonrelapse mortality at 1 year was 16% (95% confidence interval, 9%-23%) and significantly lower for patients with a completely matched donor (12% vs 38%; P = .003). The cumulative incidence of relapse at 3 years was 22% (95% confidence interval, 13%-31%) and was influenced by Lille risk profile (low, 14%; intermediate, 22%; and high, 34%; P = .02). The estimated 5-year event-free and overall survival was 51% and 67%, respectively. In a multivariate analysis, age older than 55 years (hazard ratio = 2.70; P = .02) and human leukocyte antigen-mismatched donor (hazard ratio = 3.04; P = .006) remained significant factors for survival. The study was registered at www.clinicaltrials.gov as #NCT 00599547.
M3 - SCORING: Zeitschriftenaufsatz
VL - 114
SP - 5264
EP - 5270
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 26
M1 - 26
ER -
